Andere Sprachen Moberg Pharma AB

Aktien

Verzögert Nasdaq Stockholm Andere Börsenplätze 10:57:07 15.05.2024			% 5 Tage	% 1. Jan.
26,4 ^SEK	-5,85 %		-21,71 %	+73,68 %

07.05.	Moberg Pharma AB (publ) meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
06.05.	Moberg Pharma AB gibt bekannt, dass MOB-015 die nationalen Zulassungen für alle am dezentralen Verfahren beteiligten Länder erhalten hat	CI

Bulletin from Moberg Pharma's AGM on May 14[th], 2024	14.05.
Moberg Pharma - Positive momentum	08.05.
Moberg Pharma's interim report January - March 2024	07.05.
Moberg Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	07.05.
National approval for MOB-015 in all 13 countries	06.05.
Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized Procedure	06.05.
Moberg Pharma : Launch update for MOB-015	23.04.
Moberg Pharma : Launch update for MOB-015	23.04.
Moberg Pharma AB Announces Launch Update for Mob-015	23.04.
Notice of Annual General Meeting in Moberg Pharma AB (publ)	12.04.
Moberg Pharma Annual report for 2023	12.04.
Moberg Pharma : Corporate Governance Report 2023	12.04.
Moberg Pharma : Application submitted to include an additional terbinafine supplier	08.04.
Moberg Pharma AB Submits Application to Include an Additional Terbinafine Supplier	08.04.
Certain Ordinary Shares of Moberg Pharma AB are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	26.02.
The Nomination Committee's proposal to the Annual General Meeting 2024	19.02.
Moberg Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13.02.
Moberg Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	13.02.
MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication	07.02.
Moberg Pharma's Interim report January - September 2023	07.11.

Keine Ergebnisse zu dieser Suche